Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study

2021 ◽  
Author(s):  
Geoffroy Bilger ◽  
Nicolas Girard ◽  
Hélène Doubre ◽  
Matteo Giaj Levra ◽  
Etienne Giroux-Leprieur ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retrospective Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Real Life ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer

2019 ◽  
Vol 10 (3) ◽  
pp. 526-532 ◽  
Author(s):  
Yuki Katayama ◽  
Tadaaki Yamada ◽  
Keiko Tanimura ◽  
Akihiro Yoshimura ◽  
Takayuki Takeda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Bowel Movement ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Movement Condition

Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non–Small-Cell Lung Cancer

2020 ◽  
Vol 21 (5) ◽  
pp. e405-e414
Author(s):  
Taichi Miyawaki ◽  
Hirotsugu Kenmotsu ◽  
Keita Mori ◽  
Eriko Miyawaki ◽  
Nobuaki Mamesaya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Tumor Burden ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document